In the Autumn of 2023, technical specialists from BÜHLMANN visited Great Ormond Street Children’s Hospital (GOSH) to collaboratively establish a protocol for integrating the new BÜHLMANN sCAL turbo into their Ortho Vitros analyser. This move aimed to facilitate the transition of the immunology team from the conventional ELISA method to the advanced PETIA assay for…
In 2014, the CALEX Cap transformed faecal calprotectin extraction workflows in laboratories. Now, with CALEX faecal calprotectin collection kits, patients can prepare and return their own samples, eliminating the need for traditional stool samples. The lab receives a ready-to-use CALEX, streamlining the testing process. This revolutionary shift maximises laboratory resources, reshaping calprotectin testing workflows significantly.…
An interview with Prof. Dr. Patrick van Rheenen University Medical Center Groningen, The Netherlands Can you introduce yourself and your organization? My name is Patrick van Rheenen and I work at the University Medical Centre in Groningen (the Netherlands). I am a clinical researcher into paediatric inflammatory bowel disease. How did you choose IBDoc® for…
Alison Jones, Consultant Clinical Biochemist, York and Scarborough NHS Foundation Trust It is well documented that liquid/watery stool samples should not be tested for faecal elastase due to the risk of a false low result suggesting pancreatic insufficiency (a false positive). This is not a failure of the assay – it works in exactly the…
Dr Peter Rimmer, The Queen Elizabeth Hospital, Birmingham We are all very familiar with the use of faecal calprotectin testing to help distinguish inflammatory bowel disease (IBD) from functional disorders, and it has become a staple tool to support the clinical teams in their diagnosis and management of patients. If a negative faecal calprotectin result…
Following on from the success of the fCAL® turbo and the fPELA® assays, BÜHLMANN has now launched the sCAL® turbo for serum calprotectin, that operates on the same principles as its predecessors. The BÜHLMANN sCAL® turbo runs on the mainstream clinical chemistry analysers and the time to first result is 10 minutes, with further results…
Ailsa Ralph, NHS Trainee Clinical Scientist With the onset of COVID one of the big challenges faced by many hospitals was having sufficient access to biosafety cabinets for sample handling, due to the unknown infection risk from viral RNA which could be detected in the samples. Many hospitals had to prioritise which samples/tests would be…
Kezia Allen, Associate Practitioner – Clinical Trials, Basildon Hospital The demands on healthcare resources continue to escalate, with the COVID pandemic having exacerbated the existing pressures from an aging population living longer and with more complex health conditions. Changes to traditional practices are essential if healthcare services are to keep pace with the increased demands.…
Switching to the new fPELA turbo assay for improved workflow and efficiency Kaleem Fayyaz, Blood Sciences Team Leader, Spire Manchester Hospital Spire Healthcare is a leading UK independent hospital group. It delivers high standards of care to insured, self-pay and NHS patients across 39 hospitals and 8 clinics. The laboratories at Spire Manchester Hospital provide…
From the Siemens Advia 2400 to the Atellica Analyser Georgette Glover, Senior Biomedical Scientist, Biochemistry Department, Addenbrookes Hospital Addenbrookes Hospital has been using the BÜHLMANN calprotectin assays for a number of years. They initially employed the fCAL® ELISA with the CALEX® sample extraction device, processed on a Dynex DS2 automated system. However, in December 2018…